Latest Content

Check out the pipeline updates from December!

OpenAI's shift from a nonprofit to a profit-driven entity raises concerns about user safety and ethical AI development amidst psychological consequences.

Discover groundbreaking findings on digital therapeutics and medications for schizophrenia and depression, showcasing safety and efficacy in recent studies.

Explore innovative treatments for schizophrenia, depression, and dementia, focusing on new medications and holistic care approaches for better patient outcomes.

Need CME credit? We've got you covered.

Explore innovative approaches to mental health care, from jail diversion programs to addressing burnout in female physicians, enhancing patient outcomes.

Review the news from this year's Clinical Trials in Alzheimer's Disease conference.

A psychiatric reflects on a true gift, envisioning a future of hope, healing, and inclusion and celebrating the power of unity and compassion.

See the variety of commentary, news, and happenings in artificial intelligence (AI) and psychiatry throughout this year.

Syremis Therapeutics advances innovative drugs ST-905 and ST-901 for schizophrenia and major depressive disorder, aiming to transform mental health treatment.

During the holidays, can we blend tradition with modern media habits without sacrificing the meaning?

Cobenfy gains NMPA approval in China, offering a groundbreaking treatment for schizophrenia with a unique mechanism and improved symptom management.

In this CME article, explore effective strategies for managing sleep disturbances in elite athletes, focusing on pharmacologic and nonpharmacologic interventions.